Presentation is loading. Please wait.

Presentation is loading. Please wait.

Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report  Patrick M. Forde, MD,

Published by奉漱 浦 Modified over 5 years ago

Similar presentations

Presentation on theme: "Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report  Patrick M. Forde, MD,"— Presentation transcript:

1 Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report  Patrick M. Forde, MD, Craig M. Hooker, MPH, Sosipatros A. Boikos, MD, Iacope Petrini, MD, Giuseppe Giaccone, MD, Charles M. Rudin, MD, PhD, Stephen C. Yang, MD, Peter B. Illei, MD, Christine L. Hann, MD, PhD, David S. Ettinger, MD, Julie R. Brahmer, MD, Ronan J. Kelly, MD, MBA  Journal of Thoracic Oncology  Volume 9, Issue 3, Pages (March 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan–Meier Curves of (A) time to recurrence after surgical resection and (B) overall survival from diagnosis of locally advanced or metastatic pulmonary carcinoid by histologic subtype. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report  Patrick M. Forde, MD,"

Similar presentations

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic.

A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Similar presentations

Ads by Google